Product candidates in clinical studies

Our first product candidate, ThermoDox® uses our LTSL (lysolipid thermally sensitive liposome) technology to encapsulate the commonly used cancer drug doxorubicin. The heat-sensitive liposome rapidly changes structure when heated to 40°C-45°C, creating openings that release doxorubicin directly into and around the targeted tumor. ThermoDox is currently being evaluated in clinical studies for primary liver cancer.

Our second product candidate GEN-1, uses our TheraPlas™ technology platform to provide localized immunotherapy. GEN-1 is an interleukin-12 (IL-12) DNA plasmid vector formed into nanoparticles with a lipopolymeric delivery system. It is currently under evaluation for the treatment of ovarian cancer and has also demonstrated potential efficacy benefits in glioblastoma multiforme (GBM).


Enhancing the efficacy of doxorubicin with heat-activated liposome technology


Harnessing the potential of IL-12 for targeted immunotherapy treatment